OnCusp Therapeutics

formerly OnCusp

We deliver hope to cancer patients worldwide.

Princeton, United States · Founded 2021 · $125.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$125.0M
Last Round
$100.0M Series AJan 2024
Rounds
2

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

OnCusp Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class oncology therapies, including antibody-drug conjugates (ADCs) and other targeted cancer treatments. Co-founded in 2021 by veterans from Merck, Novartis, and Daiichi Sankyo, the company advanced its lead asset CUSP06 — a CDH6-targeted ADC — into Phase 1 clinical trials and has raised $139M from investors including Novo Holdings and OrbiMed.

Summary

OnCusp Therapeutics is a Biotech company based in Princeton, United States, founded in 2021. It has raised $125.0M in total across 2 rounds, most recently a $100.0M Series A round in Jan 2024. Investors include OrbiMed, F-Prime Capital and Novo Holdings A/S.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries AJan 2024
$100.0M

Sign up to see all 2 events

Funding: Seed through Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018
Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech, Healthcare
Series DTotal funding$1.4BJun 2020
Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Alnylam PharmaceuticalsIPO

Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...

Cambridge, United States1001–5000Biotech, Genomics
Corporate RoundTotal funding$1.0BApr 2020
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

OnCusp Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/oncusp-therapeutics"><img src="https://indexed.vc/api/badge/company/oncusp-therapeutics" alt="OnCusp Therapeutics on Indexed.vc" width="260" height="76" /></a>